VIOLIN Logo
VO Banner
Search: for Help
Vaxjo Home
Introduction
Statistics
News and Updates
Vaxjo Query
Selected Adjuvants
adamantylamide dipeptide vaccine adjuvant
aluminum hydroxide vaccine adjuvant
alhydrogel vaccine adjuvant
Data Submission
Data Exchange
Data Download
Documentation
FAQs
Disclaimer
Contact Us
UMMS Logo

Vaccine Comparison

27-35(27L):MART-1 peptide vaccine
Vaccine Information
  • Vaccine Name: 27-35(27L):MART-1 peptide vaccine
  • Vaccine Ontology ID: VO_0007191
  • Type: Subunit vaccine
  • Status: Clinical trial
  • Host Species for Licensed Use: Human
  • Host Species as Laboratory Animal Model: Human
  • MLANA gene engineering:
    • Type: Recombinant protein preparation
    • Detailed Gene Information: Click Here.
  • gp100 (PMEL) gene engineering:
    • Type: Recombinant protein preparation
    • Detailed Gene Information: Click Here.
  • Tyrosinase gene engineering:
    • Type: Recombinant protein preparation
    • Detailed Gene Information: Click Here.
  • Adjuvant:
  • Adjuvant:
  • Preparation: The vaccine consisted of Melan-A/MART-1:27–35, tyrosinase: 368–376(370D), gp100:209–217(210M) and gp100:280–288(288V) peptides in Freund's adjuvant (Toso et al., 2002).
  • Description: A synthetic peptide consisting of amino acids 27 through 35 of the melanoma differentiation antigen MART-1. 27-35(27L) MART-1 has a leucine substitution at amino acid position 27 to improve binding to HLA-A*0201. Vaccination with this agent may stimulate the host immune response to mount a cytotoxic T-lymphocyte response against melanoma cells expressing MART-1. This cancer vaccine has been used in melanoma trials (NCIT_C28784; Tarhini et al., 2012)
References
NCIT_C28784: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C28784]
Tarhini et al., 2012: Tarhini AA, Butterfield LH, Shuai Y, Gooding WE, Kalinski P, Kirkwood JM. Differing patterns of circulating regulatory T cells and myeloid-derived suppressor cells in metastatic melanoma patients receiving anti-CTLA4 antibody and interferon-α or TLR-9 agonist and GM-CSF with peptide vaccination. Journal of immunotherapy (Hagerstown, Md. : 1997). 2012; 35(9); 702-710. [PubMed: 23090079].
Toso et al., 2002: Toso JF, Lapointe R, Hwu P. CD40 ligand and lipopolysaccharide enhance the in vitro generation of melanoma-reactive T-cells. Journal of immunological methods. 2002; 259(1-2); 181-190. [PubMed: 11730853].
Cancer EPCAM protein vaccine
Vaccine Information
  • Vaccine Name: Cancer EPCAM protein vaccine
  • Vaccine Ontology ID: VO_0011370
  • Type: Subunit vaccine
  • Status: Research
  • Antigen: EPCAM (GA733)
  • EPCAM gene engineering:
    • Type: Recombinant protein preparation
    • Detailed Gene Information: Click Here.
  • Adjuvant:
  • Immunization Route: subcutaneous injection
References
 
Cancer Her-2/neu Protein Subunit Vaccine
Vaccine Information
  • Vaccine Name: Cancer Her-2/neu Protein Subunit Vaccine
  • Vaccine Ontology ID: VO_0011363
  • Type: Subunit vaccine
  • Status: Research
  • Antigen: ERBB2
  • ERBB2 gene engineering:
    • Type: Recombinant protein preparation
    • Detailed Gene Information: Click Here.
  • Adjuvant:
    • VO ID: VO_0001147
    • Description: Gerbu Adjuvant and recombinant IL-2 (Wagner et al., 2007).
  • Adjuvant:
  • Immunization Route: Intramuscular injection (i.m.)
References
 
Cancer Subunit GV1001 Protein Vaccine
Vaccine Information
References
 
Cancer Subunit NY-ESO-1 Protein Vaccine
Vaccine Information
References
 
Cancer Vaccine using E7 protein of human papillomavirus 16 and Algammulin
Vaccine Information
References
Fernando et al., 1998: Fernando GJ, Stewart TJ, Tindle RW, Frazer IH. Th2-type CD4+ cells neither enhance nor suppress antitumor CTL activity in a mouse tumor model. Journal of immunology (Baltimore, Md. : 1950). 1998; 161(5); 2421-2427. [PubMed: 9725239].
Cancer Vaccine using E7 protein of human papillomavirus 16 and Quil-A
Vaccine Information
References
Fernando et al., 1998: Fernando GJ, Stewart TJ, Tindle RW, Frazer IH. Th2-type CD4+ cells neither enhance nor suppress antitumor CTL activity in a mouse tumor model. Journal of immunology (Baltimore, Md. : 1950). 1998; 161(5); 2421-2427. [PubMed: 9725239].
Cancer VEGFA protein vaccine
Vaccine Information
  • Vaccine Name: Cancer VEGFA protein vaccine
  • Vaccine Ontology ID: VO_0011371
  • Type: Subunit vaccine
  • Status: Research
  • Antigen: VEGFA
  • VEGFA gene engineering:
    • Type: Recombinant protein preparation
    • Detailed Gene Information: Click Here.
  • Adjuvant:
    • VO ID: VO_0000127
    • Description: Aluminum hydroxide, VSSP, and CAF01
  • Immunization Route: subcutaneous injection
References
 
PSA/IL-2/GM-CSF Vaccine
Vaccine Information
  • Vaccine Name: PSA/IL-2/GM-CSF Vaccine
  • Vaccine Ontology ID: VO_0007153
  • Type: Subunit vaccine
  • Status: Clinical trial
  • Host Species for Licensed Use: Human
  • Host Species as Laboratory Animal Model: Human
  • IL12 gene engineering:
    • Type: Recombinant protein preparation
    • Description: (Fujio et al., 2015)
    • Detailed Gene Information: Click Here.
  • GM-CSF (human) gene engineering:
  • Adjuvant:
  • Preparation: SGE plasmid encoding a fusion protein of full-length human PAP and one of the cytokines (human GMCSF, IL2, IL4, IL7 or mouse GMCSF or IL4) were then constructed and used to express the recombinant PAP-fused cytokines (Fujio et al., 2015).
  • Description: This is for Prostate Cancer (NCT02058680). A prostate cancer vaccine containing prostate specific antigen (PSA) combined with the cytokines, interleukin-2 (IL-2) and granulocyte macrophage-colony-stimulating factor (GM-CSF), with potential antineoplastic activity. Upon intradermal vaccination, PSA/IL-2/GM-CSF vaccine may activate the immune system to induce a cytotoxic T-cell (CTL) response against prostate cancer cells expressing this antigen, thereby decreasing tumor cell growth. PSA, a glycoprotein secreted by prostatic epithelial and ductal cells, is overexpressed by prostate cancer cells. IL-2 stimulates natural killer (NK) cells and cytotoxic T-cells against the PSA-expressing tumor cells. GM-CSF promotes antigen presentation to dendritic cells and further stimulates a tumor-specific cytotoxic T-lymphocyte (CTL) response (Onaitis et al., 2002; NCIT_C114289).
References
Fujio et al., 2015: Fujio K, Watanabe M, Ueki H, Li SA, Kinoshita R, Ochiai K, Futami J, Watanabe T, Nasu Y, Kumon H. A vaccine strategy with multiple prostatic acid phosphatase-fused cytokines for prostate cancer treatment. Oncology reports. 2015; 33(4); 1585-1592. [PubMed: 25632844].
NCIT_C114289: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C114289]
NCT02058680: Phase 1A/1B Study of PSA/IL-2/GM-CSF Vaccine for Recurrent Prostate Cancer in Hormone Naive and Hormone Independent Patients (PSA) [https://clinicaltrials.gov/ct2/show/NCT02058680]
Onaitis et al., 2002: Onaitis M, Kalady MF, Pruitt S, Tyler DS. Dendritic cell gene therapy. Surgical oncology clinics of North America. 2002; 11(3); 645-660. [PubMed: 12487060].
Recombinant Colorectal cancer antigen GA733 Vaccine
Vaccine Information
References
Basak et al., 2000: Basak S, Eck S, Gutzmer R, Smith AJ, Birebent B, Purev E, Staib L, Somasundaram R, Zaloudik J, Li W, Jacob L, Mitchell E, Speicher D, Herlyn D. Colorectal cancer vaccines: antiidiotypic antibody, recombinant protein, and viral vector. Annals of the New York Academy of Sciences. 2000; 910; 237-252. [PubMed: 10911917].
Recombinant NY-ESO-1 ISCOMATRIX Vaccine
Vaccine Information
References
Nicholaou et al., 2009: Nicholaou T, Ebert LM, Davis ID, McArthur GA, Jackson H, Dimopoulos N, Tan B, Maraskovsky E, Miloradovic L, Hopkins W, Pan L, Venhaus R, Hoffman EW, Chen W, Cebon J. Regulatory T-cell-mediated attenuation of T-cell responses to the NY-ESO-1 ISCOMATRIX vaccine in patients with advanced malignant melanoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2009; 15(6); 2166-2173. [PubMed: 19276262].
Recombinant NY-ESO-1 Protein vaccine adjuvanted with Imiquimod
Vaccine Information
  • Vaccine Name: Recombinant NY-ESO-1 Protein vaccine adjuvanted with Imiquimod
  • Vaccine Ontology ID: VO_0004248
  • Type: Subunit vaccine
  • Status: Clinical trial
  • Antigen: Recombinant, full-length NY-ESO-1 protein (Adams et al., 2008).
  • CTAG1B gene engineering:
    • Type: Recombinant protein preparation
    • Detailed Gene Information: Click Here.
  • Adjuvant:
  • Immunization Route: Intradermal injection (i.d.)
  • Description: Recombinant, full-length NY-ESO-1 protein was administered intradermally into imiquimod preconditioned sites followed by additional topical applications of imiquimod in patients with malignant melanoma (Adams et al., 2008).
References
Adams et al., 2008: Adams S, O'Neill DW, Nonaka D, Hardin E, Chiriboga L, Siu K, Cruz CM, Angiulli A, Angiulli F, Ritter E, Holman RM, Shapiro RL, Berman RS, Berner N, Shao Y, Manches O, Pan L, Venhaus RR, Hoffman EW, Jungbluth A, Gnjatic S, Old L, Pavlick AC, Bhardwaj N. Immunization of malignant melanoma patients with full-length NY-ESO-1 protein using TLR7 agonist imiquimod as vaccine adjuvant. Journal of immunology (Baltimore, Md. : 1950). 2008; 181(1); 776-784. [PubMed: 18566444].
Synthetic MUC1 Peptide Vaccine
Vaccine Information
  • Vaccine Name: Synthetic MUC1 Peptide Vaccine
  • Vaccine Ontology ID: VO_0004258
  • Type: Subunit vaccine
  • Status: Research
  • Antigen: The 140-aa synthetic MUC1 peptide (Soares et al., 2001).
  • MUC1 gene engineering:
    • Type: Recombinant protein preparation
    • Description: This article lays out the relationship between MUC1 and tumor growth used in cancer vaccines. (Soares et al., 2001)
    • Detailed Gene Information: Click Here.
  • Adjuvant:
  • Immunization Route: subcutaneous injection
References
Soares et al., 2001: Soares MM, Mehta V, Finn OJ. Three different vaccines based on the 140-amino acid MUC1 peptide with seven tandemly repeated tumor-specific epitopes elicit distinct immune effector mechanisms in wild-type versus MUC1-transgenic mice with different potential for tumor rejection. Journal of immunology (Baltimore, Md. : 1950). 2001; 166(11); 6555-6563. [PubMed: 11359807].